Dose-Reduced Allogeneic Stem Cell Transplantation as Induction of a Graft-Versus-Myeloma-Effect After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma Stage II/III
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and efficacy of a conditioning regimen with Fludarabine, Melphalan and ATG prior allogeneic SCT after high dose chemotheraoie and autologous SCT. Evaluation of underlying disease and donor-recipient-chimerism.
Yes
Nicolaus Kroeger, Prof. Dr.
Principal Investigator
University Medical Center Hamburg-Eppendorf, Germany
Germany: Federal Institute for Drugs and Medical Devices
Auto/Allo Plasmozytom
NCT00781170
May 2000
Name | Location |
---|